SCHEMBL5934290

SCHEMBL5934290

COc1ccccc1-c1ccc(C(=O)Nc2ccc(Br)c(C(F)(F)F)c2)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.56
▸ LMNA P02545 4/20 0.56
▸ MEN1 O00255 3/20 0.56
▸ KMT2A Q03164 3/20 0.56
▸ HTT P42858 3/20 0.54
▸ NPSR1 Q6W5P4 2/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ XBP1 P17861 1/20 0.54
▸ S1PR1 P21453 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ GRM4 Q14833 1/20 0.47
▸ KDR P35968 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ WNT3A P56704 3/20 0.47
▸ EPHX1 P07099 1/20 0.46
▸ TRPV1 Q8NER1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5934707 0.86 MAPT (0.61) MAPTLMNAMEN1KMT2AHTT
SCHEMBL5934704 0.85 MAPT (0.54) MAPTLMNAMEN1KMT2AHTT
SCHEMBL5934561 0.84 TRPV1 (0.60) MEN1KMT2ANPC1RAB9AKDR
SCHEMBL5934470 0.81 RAB9A (0.53) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL5934752 0.80 WNT3A (0.53) MAPTLMNAGRM4WNT3ACDK9
SCHEMBL5934181 0.80 MEN1 (0.55) MAPTLMNAMEN1KMT2AHTT
SCHEMBL5934372 0.79 NPC1 (0.60) KMT2ANPC1RAB9ASMN1; SMN2GRM4
SCHEMBL5934383 0.78 MEN1 (0.59) MAPTLMNAMEN1KMT2AHTT
SCHEMBL5934132 0.78 HDAC3 (0.53) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL5934343 0.77 RAB9A (0.58) MAPTLMNAMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1575918-A2 SUBSTITUTED BIARYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2005-09-21 — — EP claimed
WO-2004056774-A2 SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2004-07-08 — — WO claimed
US-20060100245-A1 Substituted biphenyl-4-carboxylic acid arylamide analogues NEUROGEN CORPORATION (US) 2006-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100245-A1 Substituted biphenyl-4-carboxylic acid arylamide analogues HCAR2, AHR, HCAR3 MAPT 3567/4885LMNA 3719/4885MEN1 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback